“…The mitoxantrone concentrations required for the stimulation of eryptosis are within the range of mitoxantrone concentrations required for the antineoplastic activity of the substance [46]. At least in theory, the erythrocytes could be sensitized to the effect of mitoxantrone by parallel exposure to further eryptosis triggering xenobiotics [28,39,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73]. Moreover, the sensitivity to mitoxantrone may be increased in patients suffering from disorders with enhanced eryptosis [28], such as diabetes [34,74,75], dehydration [76], renal insufficiency [77,78], hemolytic uremic syndrome [79], sepsis [80], malaria [81], sickle cell disease [81], Wilson's disease [82], iron deficiency [83], malignancy [84], phosphate depletion [85], and metabolic syndrome [65].…”